Abstract. Purine analogs modified in the 5-membered ring have been synthesized and examined for antibacterial activity against Mycobacterium tuberculosis H 37 Rv in vitro employing the microplate alamar blue assay (MABA). The 9-deaza analogs were only found to be weak inhibitors, but the 8-aza-, 7-deaza-and 8-aza-7-deazapurine analogs studied displayed excellent antimycobacterial activities, some even substantially better than the parent purine. In the 7-deazapurine series, MIC values between 0.08 and 0.35 µM, values comparable or better than the reference drugs used in the study (MIC rifampicin 0.09 µM, MIC isoniazid 0.28 µM and MIC PA-824 0.44 µM). The five most active compounds were also examined against a panel of drug-resistant Mtb strain, and they all * to whom correspondence should be addressed. Tel.: +4722857019; Fax: +22855507; E-mail: l.l.gundersen@kjemi.uio.no retained their activity. The compounds examined were significantly less active against M. tuberculosis in a state of non-replicating persistence (NRP). MIC in the low-oxygen-recovery assay (LORA) ≥ 60 µM. The 7-deazapurines were somewhat more toxic towards mammalian cells, but still the selectivity indexes were excellent. The non-purine analogs exhibit a selective antimycobacterial activity. They were essentially inactive against Staphylococcus aureus and Escherichia coli.
Introduction
We have previously reported that certain 6,9-disubstituted purines are potent inhibitors of
Mycobacterium tuberculosis (Mtb) in vitro.
1 These antimycobacterial purines display several properties which make them highly interesting as potential drugs against tuberculosis. These are high selectivity towards Mtb compared to other microorganisms, activity against several drug resistant strains of Mtb, generally low toxicity towards mammalian cells, and ability to affect Mtb inside macrophages. Figure 1 summarizes the current SAR knowledge as well as the structures of some of the most active compounds in this series.
( Fig. 1) Tuberculosis (TB) still claims ca. 2 million deaths pr. year worldwide and resistance to existing drugs is a growing problem. Thus there is an urgent need for novel drugs for the treatment of TB.
Agents that reduce the duration and complexity of the current therapy would have a major impact on the overall cure rate. 2 After exploring SAR of intact purines ( Fig. 1) , we now focus on nonpurine analogs of compounds 1. 3 Certain pyrimidine analogs (general structure B, Fig. 1 ) display activity comparable with the parent purine, 3b,3d but simple imidazole analogs (general structure C, Fig. 1 ) are only moderately active. 3c Herein we report the synthesis and antimycobacterial activities for purine analogs modified in the 5-membered ring (general structure D, Fig. 1 ).
Chemistry
The 8-azapurine 5 was readily available from the pyrimidine 2 as shown in Scheme 1. The synthesis of 7-deaza-8-azapurine 6 (Fig. 2) has been published by us before. In contrast with what has been reported for alkylation of the 7-deazapurine 7a, 4, 5 the benzylation shown in Scheme 2 went to completion at ambient temperature, and was reasonably regioselective.
Compound 8a was isolated in 81% and only minor amounts of more polar products (not isolated)
were observed. Compound 8b was prepared in high yield from the corresponding dichloro-7-deazapurine 7b. Compounds 9a -d were synthesized by Stille couplings on the chlorides 8.
Reactions on the dichloride 8b were conducted at milder conditions in order to achieve complete regioselectivity. Finally the methoxy compound 9e was formed by exchange of the chloride in compound 9c. This is analogous with the previously reported synthesis of the 2-methoxypurine 1e
9-Alkyl-9-deazapurines have been synthesized by time-consuming construction of the bicyclic ring system via pyrroles 6 or pyrimidines, 7 and alkyl-or acyl substituents have been introduced at C-9 in 6-oxo-9-deazapurines be Friedel-Craft alkylation or acylation, but the yields are generally quite modest. 8 Instead, we evaluated several routes for the synthesis of our target 9-deazapurines 16 and 17 (Scheme 3), starting from 6-chloro-9-deazapurine (4-chloropyrrolo[3,2-d] pyrimidine) (10) . The 4, pyrimidine 13a were available be N-methylation and halogenation of compound 10. Attempts to introduce the p-methoxybenzyl substituent at C-9 by Negishi couplings on the halide 13a or the corresponding 7-iodo compound (not shown), met with little success. 9-Deazapurine can be lithiated at C-9 by metal-halogen exchange and the lithiated species may react with for instance imines 7b,9 or amides. 6c However, attempts to introduce the desired C-9 substituent by lithiation of compound 13a followed by reaction with p-methoxybenzyl halides failed. This was in part due to migration of lithium to C-8 before reaction with the alkyl halide. Also reactions between lithiated 13a and anisaldehyde, the corresponding Weinreb amide, or benzoyl chloride turned out to be sluggish reactions. In our hands, the best route to the target molecule 17 is the one shown in Scheme 3. Lithiated 13a was trapped with DMF to give the aldehyde 14a in a high yield.
Compound 14a was subsequently reacted with p-methoxyphenylmagnesium bromide. The secondary alcohol thus formed turned out to be difficult to isolate in pure form, but the adduct was instead subjected to in situ Oppenaur oxidation by benzaldehyde in the presence of LiCl 10 to give the ketone 15a. After introduction of the furyl group by a Stille coupling on the chloride 15a, ketone 16a was reduced to the target 17 under Wolff-Kishner conditions. Several other reduction methods were unsuccessful for this transformation.
Silyloxymethyl chlorides have been developed as reagents for N-11 and O-protection, 12 and the protected compounds can be cleaved when treated with fluoride ions under milder conditions than normally required to cleave the analogous SEM-protected derivatives. The only commercially available of these reagents is (triisopropylsilyloxy)methyl chloride (TOM-Cl), 13 and we chose the TOM group as N-protection group in the synthesis of target compound 16c. The N-protected ketone 16b was synthesized as described for compound 16a above, and the protection group was conveniently removed by KF in methanol. The protection group was not compatible with the harsh conditions required in a Wolff-Kishner reduction, nor was the reduction of the carbonyl group compound 16c successful. However, the 9-deazapurines 16a, 16c and 17 all turned out to be far less active as antimycobacterial compounds compared to the parent purine and the other non-purine analogs reported herein (see below), and no further attempts were made to synthesize an analog of compound 17 with a free NH-group.
(Scheme 3)
Biological evaluation
The target compounds 5, 6, 9a -9e, 16a, 16c and 17 were screened for activity against M.
tuberculosis H 37 Rv (ATCC #27294) in the microplate alamar blue assay (MABA) 14 and the MIC values are given in Table 1 . The previously synthesized purines 1a and 1b were included for comparison. The substituents are defined in Fig. 1 , and the detailed structures can be found in Fig. 2 and Schemes 1 -3. (Table 1) The deazapurines 16 and 17 were only weak inhibitors of antimycobacterial growth (MIC > 90 µM). The low activities found discouraged us from synthesis of more compounds in this series as described above, and no further examination of antimycobacterial activities was done for these substances.
The 8-azapurine 5 and the 8-aza-7-deazapurine 6 were slightly less active than the parent purine 1a,
showing that the purine C-8 may be exchanged with a nitrogen without a significant loss of activity.
However, the most intriguing results were found for the 7-deazapurines 9. Compound 9a was ca. 8 times more active than the parent purine 1a. The thienyl derivative 9b appeared to be a slightly weaker inhibitor than the furyl derivative 9a. The same tendency has been observed in the purine series before. 1 In our study of the purines, we have generally seen that antimycobacterial activity is substantially increased when chlorine is introduced in the 2-position, 1 and compounds 9c and 9d
were the among the most active in this series. The values were in the same range as for the drug rifampicin and better than for isoniazid or the promising drug candidate PA-824. 15 In case of tuberculosis, a sub-population of the bacteria isolate in a state of non-replicating persistence (NRP). NRP is considered to be an important factor contributing to the long treatment duration (≥6 months required). Hence we wanted to investigate if the antimycobacterial purines and non-purine analogs described herein also could affect Mtb in NRP. Compounds 1a, 1b, 5, 6 and 9a -9e were thus tested in the low-oxygen-recovery assay (LORA) 16 (Table 1) . Unfortunately, as also seen for many known antituberculosis drugs 16 including izoniazid, the compounds were not found to be very active in this assay. Interestingly, it seems likely that the thienyl substituent results in somewhat more active compounds, and that the chloride is not beneficial for activity in the LORA.
The best inhibitor identified in this assay was the thienyl-7-deazapurine 9b (MIC 60 µM).
The antimycobacterial purine analogs 5, 6 and 9a -9e were examined for toxicity against mammalian cells (VERO cells), and low EC 50 values were found (Table 1 ). All deazapurines 9 were more toxic towards VERO cells than compounds 1, 5 and 6, but the selectivity indexes (SI) were still very good for these antimycobacterial compounds. For the best inhibitor of Mtb growth, compound 9c, the SI was found to be > 1000.
The five most active deazapurines (9a -9e) as well as the parent purine 1b were examined against a panel of Mtb strains resistant to currently used anti-TB drugs; rifampicin (RMP), isoniazid (INH), streptomycin (SM), kanamycin (KM) and clofazimine (CLF) ( Table 2 ). All compounds examined retained their activity against all the drug resistant strains applied in this study.
( Table 2) In accordance with previous findings on the structurally related purines, 1 the non-purine analogs exhibit a selective antimycobacterial activity. Compounds 5, 6, 9a, 9c, 16a, 16c and 17 were tested against Staphylococcus aureus and Escherichia coli and were found to be essentially inactive (all MICs > 32 µg/mL; >90 µM). Even though the mode of action for our purines and non-purine analogs is not known, the lack of cross resistance and lack of actiity towards other bacteria points towards a novel mechanism of action and a target not found in all bacteria.
In summary, novel 8-aza-, 7-deaza-9-deaza and 8-aza-7-deazapurines have been synthesized and their biological activities have been compared with those of known antimycobacterial purines with similar substitution patterns. It was found that the purine N-9 is important for activity, since the 9-deazapurines studied were only weak inhibitors of Mtb in the MABA. The purine C-8 may be exchanged with nitrogen without significant loss of activity and removal of the purine N-7 results in substantially improved growth inhibition. The best results were obtained for some of the 7-deazapurines with MIC in the MABA comparable with rifampicin. The compounds studied were generally of low toxicity towards mammalian (VERO) cells and essentially inactive against other bacteria (S. aureus, E. coli). Unfortunately, the compounds studied were not found to be very active against Mtb isolates in NRP.
Experimental
The 1 H NMR spectra were recorded at 500 MHz with a Bruker Avance DRX 500 instrument, at 300 Antimycobacterial data.
Minimum inhibitory concentrations (MIC) against replicating and non-replicating cultures of
Mycobacterium tuberculosis were determined using the microplate Alamar Blue assay (MABA) 14 and low oxygen recovery assay (LORA), 16 respectively. The former was determined against M.
tuberculosis H 37 Rv ATCC 27294 (American Type Culture Collection) as well as drug-resistant Mtb strains following 7 days incubation with test samples. The latter was determined against low oxygen adapated M. tuberculosis H 37 Rv luxAB carrying a luciferase reporter gene following 10 days incubation under low oxygen followed by 28 hours of normoxic recovery. Both assays were conducted in microplate format in 7H12 medium. 14b The MIC was defined as the lowest concentration effecting a reduction of ≥90% in fluorescence (MABA) or luminescence (LORA)
relative to untreated controls. was added to the residue and the mixture stirred for 18 h. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:2) followed by EtOAc-hexane 
7-Chloro-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4)
.
2,4-Dichloro-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (8b). The title compound was
synthesized from 2,4-7-deazapurine 7b (1.25 g, 6.65 mmol) following the procedure for synthesis of compound 8a. The product was purified by flash chromatography on silica gel eluting with 129.4 (CH in Ar and C-6), 152.0 (2 × C, C-2 / C-4 / C-7a), 152.6 (C-2 / C-4 / C-7a), 159.6 (C-4 in Ar); MS EI m/z (rel. %) 309 / 307 (6 / 10, M + ), 122 (9), 121 (100), 91 (3), 90 (1), 78 (7), 77 (5) 
4-(2-Furyl)-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9a
EI m/z (rel. %) 321 (39, M + ), 306 (1), 214 (1), 200 (1), 122 (9), 121 (100), 78 (7), 77 (6
2-Chloro

2-Chloro-7-(4-methoxybenzyl)-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine (9d
4-(2-Furyl)-2-methoxy-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9e). A solution of
4-Chloro-7-bromo-5H-pyrrolo[3,2-d]pyrimidine (11).
18 N-Bromosuccinimide (0.30 g, 1.7 mmol) was added in small portions to a well stirred solution of 10 (0.20 g, 1.3 mmol) in THF (10 mL) under N 2 -atm., the resulting reaction mixture was stirred at ambient temperature for 2 h. A small amount of silica gel was added and the mixture was evaporated. The residue was added on top of a silica gel flash chromatography column, and the product was isolated after elution with CH Acetic acid (1 mL) was added and the resulting suspension was stirred for 15 min, before the solvents were evaporated in vacuo. The residue was dissolved in EtOAc (50 mL) and washed with sat. aq. NaHCO 3 (25 mL) and water (25 mL). The aq. phases were extracted with EtOAc (25 mL) and the combined EtOAc extracts were dried (MgSO 4 ) and evaporated in vacuo. The product was used without further purification; yield 508 mg (93%), off-white solid. 
7-Bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (13a).
Method A: NaH (27 mg, ca. 0.68 mmol, ca. 60% in oil,) was added in small portions to a well stirred solution of 11 (80 mg, 0.34 mmol) in dry DMF (2 mL) at 0 °C under N 2 -atm. The reaction mixture was stirred for 1 h at 0 °C before iodomethane (0.021 mL, 0.34 mmol) was added dropwise. The reaction mixture was allowed to gradually reach ambient temperature over 1.5 h and subsequently cooled to 0 °C. Glacial acetic acid (0.1 mL) was added and resulting suspension was stirred for 10 min, before the solvents were evaporated in vacuo. and evaporated. The product was purified by flash chromatography on silica gel eluting with MeOH-CH 2 Cl 2 (1:99); yield 460 mg (76%).
7-Bromo-4-chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidine (13b). NaH
(51 mg, ca. 1.3 mmol, ca. 60% in oil) was added to a solution of 11 (250 mg, 1.07 mmol) in DMF (4 mL) at 0 o C. The reaction mixture was stirred at this temperature under N 2 -atm. for 1h, before (triisopropylsilyloxy)methyl chloride (0.30 mL, 1.3 mmol) was added dropwise. The reaction mixture was allowed to reach ambient temperature over 2 h before it was cooled to 0 o C and few drops of water were added. The solvent was evaporated in vacuo, the residue was suspended in water (40 mL) and was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (100 mL), dried (MgSO 4 ) and evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane 
4-Chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidine-7-carbaldehyde (14b).
The product was synthesized from compound 13b (240 mg, 0.570 mmol) as described for the synthesis of compound 14a above and the product was isolated by flash chromatography eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane (1:4); yield 180 mg, (86% 
4-(2-Furyl)-7-(4-methoxybenzyl)-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (17).
A suspension of 16a (95 mg, 0.29 mmol) in ethylene glycol (3.0 mL) and hydrazine hydrate (0.28 mL, 5.7 mmol) was heated until a clear solution was obtained (ca. 10 min, ca. 70 °C) before crushed NaOH (228 mg, 5.70 mmol) was introduced. The resulting mixture was heated at 120 °C for 18 h before the reaction mixture was cooled to 0 °C and neutralized by dropwise addition of 10% aq. HCl with stirring. After complete neutralization, water (20 mL) was added and resulting mixture was extracted with EtOAc (5 × 20 mL). The combined organic phases were washed with water (50 mL)
followed by brine (50 mL), dried (MgSO 4 ) and evaporated in vacuo. Fig. 1 . SAR summary for antimycobacterial purines A, structures of some of the most active purines (1a-1f), general structures of pyrimidine-B and imidazole analogs C and general structure of the target compounds D described in this study. ( Fig 1) ( Fig 2) (Scheme 1) (Scheme 2) (Scheme 3)
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